Key result
Daratumumab-based therapy and PA pressure-guided diuresis resolve severe high-output heart failure in POEMS syndrome.
Why the study?
Extravascular volume overload is common in POEMS syndrome, a rare vascular endothelial growth factor-driven disorder, but sustained high-output heart failure is rarely recognized.
Case Report (n=1)
This case report highlights that POEMS syndrome can cause VEGF-mediated high-output heart failure with low systemic vascular resistance that responds to hemodynamic stabilization and plasma-cell-directed therapy (daratumumab, carfilzomib, and dexamethasone).
Answers are grounded in this paper and cite their sources.
Plasma-cell therapy may resolve VEGF-mediated high-output HF in POEMS; hypothesis-generating and requires prospective validation before adoption.
BACKGROUND: POEMS syndrome, defined by polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-cell disorder, and skin changes, is a rare vascular endothelial growth factor-driven disorder. Although extravascular volume overload is common, sustained high-output heart failure (HOHF) is rarely recognized. CASE SUMMARY: ) and low filling pressures. Pulmonary artery pressure-guided diuresis and hemodialysis stabilized hemodynamics. Daratumumab/carfilzomib/dexamethasone yielded partial metabolic response with resolution of ascites, edema, and neuropathy. DISCUSSION: This case illustrates vascular endothelial growth factor-mediated vasodilation and capillary leak as a mechanism of HOHF in POEMS, with sustained response to plasma-cell-directed therapy. TAKE-HOME MESSAGE: POEMS should be considered in unexplained HOHF with low systemic vascular resistance, and new symptoms in patients with coexisting coronary disease require reassessment beyond the index diagnosis.
No takes yet. Share an insight, caveat, or question.
Keykhaei et al. (2026) conducted a case report in High-output heart failure in POEMS syndrome (n=1). Daratumumab, carfilzomib, and dexamethasone with pulmonary artery pressure-guided diuresis and hemodialysis was evaluated on Resolution of high-output heart failure symptoms and metabolic response. Daratumumab, carfilzomib, and dexamethasone with PA pressure-guided diuresis stabilized hemodynamics and resolved ascites, edema, and neuropathy in 1 patient with POEMS-related HOHF.
Synapse has enriched 10 related papers. Consider them for comparative context: